Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2Sign in
← Cases

AKT2

RBC: AKT2 · Substrate: Crosstide ·

Top inhibitors

MeasuredDerived
DrugInhibition %Gini
Capivasertib95.30.64
Netarsudil25.20.68
Midostaurin21.10.50
Sunitinib20.40.52
Ponatinib19.50.53
Acalabrutinib13.20.67
Quizartinib12.80.74
Crizotinib12.50.58
Tepotinib11.50.73
Abemaciclib11.40.56
Vandetanib9.70.72
Pirtobrutinib9.10.66
Neratinib9.00.60
Ibrutinib7.50.72
Vemurafenib7.20.60

Known variants

Cancer associations

MutationCancer typeOrganSource
E17Kcarcinoma_lungLunghttps://doi.org/10.1093/nar/gkaa945
E17Kcarcinoma_urinary_tractBladderhttps://doi.org/10.1093/nar/gkaa945
E17Kcarcinoma_breastBreasthttps://doi.org/10.1093/nar/gkaa945
E17Kcarcinoma_thyroidThyroidhttps://doi.org/10.1093/nar/gkaa945
E17Kcarcinoma_upper_aerodigestive_tractBrain/CNShttps://doi.org/10.1093/nar/gkaa945
E17KBRCA-EUBreasthttps://doi.org/10.1093/nar/gkaa945
E17KBRCA-UKBreasthttps://doi.org/10.1093/nar/gkaa945
E17KLUSC-USLunghttps://doi.org/10.1093/nar/gkaa945
E17KSKCA-BRSkinhttps://doi.org/10.1093/nar/gkaa945
E17KTHCA-USThyroidhttps://doi.org/10.1093/nar/gkaa945
E17KLUSCLunghttps://doi.org/10.1093/nar/gkaa945
E17KTHCAThyroidhttps://doi.org/10.1093/nar/gkaa945
Open in new tab